Chiang Mai Journal of Science

     Prostate cancer antigen 3 (PCA3) screening has the potential to detect prostate cancer early and assess the efficacy of surgery or radiation therapy. Nanotechnology integration in biosensor development enables effective targeted biomarker detection. Diagnosis of prostate cancer via PCA3 biomarker detection is promising to be much more efficient than with the prostatic-specific antigens currently used. In this study, we developed a GO/PCA3 marker on a surface acoustic wave (SAW) biosensor. The GO-modified SAW biosensor was prepared by conjugating GO onto L-Cysteine on the SAW chip surface. Afterward, the PCA3 capture probe was immobilized on the GO surface, and characterization was performed with XRD, SEM, AFM, and FTIR techniques. This result confirmed the successful deposition of GO, increasing the number of binding sites for interaction between GO and PCA3 capture probe through enhanced sensor surface area. The effects of EDC-NHS activation time, capture probe concentration, and incubation time were optimized. The sensor has a wide linear response that extends from 1.00 fM to 1.00 μM of PCA3 target, and the limit of detection (LOD) is 0.27 nM. These characteristics make the SAW device a promising candidate for various clinical and rapid detection applications.